Weight loss jabs are more likely to make women bald if their injection of choice is Mounjaro, a new study has found.Female users of the supposed 'King Kong' of slimming jabs are nearly twice as likely to suffer the unfortunate side effect, compared to those on rival drugs Wegovy and Ozempic. Earlier this month US researchers found that the popular injections - used by some 1.6 million Britons - are 70 per cent more likely to make you bald than other medications used to treat diabetes. The new study, by Australian scientists, found new-onset alopecia, or baldness, affects some one in 18 women within the first year of using Mounjaro, compared to one in 30 on semaglutide - the active ingredient in Wegovy and Ozempic. Experts have previously called for further research into the potential link, with patient information leaflets for both Mounjaro and Wegovy listing hair loss as a common side effect. Scientists have suggested the effect is likely due to rapid weight loss - and its associated nutritional deficiencies - rather than the jabs themselves. Weight loss jab-associated hair loss is typically a form of non-scarring alopecia, meaning the hair follicles remain intact and hair can grow back.The study, by health research firm nference, compared 11,046 patients taking Mounjaro with the same number taking semaglutide. Weight-loss drugs like Mounjaro increase the risk of hair loss, new research suggestsResults found that roughly four per cent of Mounjaro users developed hair loss, compared to just under three per cent of those using other GLP-1s and diabetes medication.However when the scientists looked at women alone, they found a starker difference between the drugs. Around six per cent of female Mounjaro injectors suffered the side effect, compared to three per cent on other jabs.The risk of hair loss was also higher among Mounjaro users regardless of how much weight patients lost or the dose they received. However, the researchers said the findings may partly reflect the fact that women are more likely to seek medical help for hair loss, which which can carry a significant social stigma.'This supports more individualised counselling and surveillance rather than a generic message that weight loss itself inevitably causes hair loss,' Venky Soundararajan, researcher and the study's lead author, said. Alopecia was found to be more common in patients with thyroid disease, and other hormonal-related conditions - suggesting underlying hormonal, or metabolic factors may contribute to the risk. Weight loss jabs, known medically as GLP-1 agonists, work by slowing the emptying of the stomach, reducing feelings of hunger that trigger overeating.